Mr. Speaker, I assure the member that there are no shortcuts when it comes to clinical trials. In fact, the bill, through the life cycle approach, is much more effective in ensuring the safety of Canadians because it would allow the government to monitor the products after they reach the market.
I will also address a concern raised by the Bloc. Proactive measures have been taken by the minister and the government. It has been demonstrated with the presentation of Bills C-51 and C-52. It has been demonstrated again in budget 2008 in which $113 million has been invested to ensure that we will have a food and consumer safety action plan that is well funded.
Will the member agree that a life cycle approach is the right way to go and that it is important for the Minister of Health to have the ability, in rare but extreme cases, to remove a product off the shelf? Those are really the main points of the bill. I hope the member will be open to accepting that the government is on the right track without predetermining, what is so often the case, negativity.
Does the member agree with the life cycle approach and mandatory recall, if necessary?